ORIC

ORIC Pharmaceuticals, Inc.
CAPPED RATING

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc. (ORIC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (D+). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.7
EV / EBITDA -3.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -41.3%
Price Return 12M -37.0%
Catalyst Signal 0.00
Market Cap $814.7M
TTM Revenue N/A
Price / Sales N/A
ROE -39.8%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) D+ (1.6) C- (2.1) B- (2.9) C+ (2.6) C (2.3)
2026-11-07 C+ (2.5) D+ (1.6) C- (2.1) C+ (2.8) C+ (2.7) C (2.3)
2026-10-31 C+ (2.5) D+ (1.5) C (2.3) B- (3.1) C+ (2.7) C (2.4)
2026-10-24 C+ (2.5) D+ (1.5) C (2.2) B (3.3) C+ (2.6) C (2.4)
2026-10-17 C+ (2.5) D+ (1.5) C (2.2) B (3.3) C+ (2.6) C (2.4)
Page 1 of 3